The National Eye Institute (NEI) awarded a 4-year, $1,313,945 Project Grant (CFDA 93.867 - Vision Research) to the University of Arizona to develop a long-acting topical nanomedicine therapy for the treatment of ocular herpes simplex virus (HSV) infections. The project aims to repurpose and reformulate the drug adefovir dipivoxil (ADV) to improve its topical delivery and reduce dosing frequency compared to currently approved treatments. Key objectives include evaluating ADV solution versus...
This $841,397 federal project grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel, multi-compartment intravaginal ring (IVR) for preventing genital herpes (HSV) and unintended pregnancy. The project aims to integrate key innovations, including: (1) an antiviral peptide lead candidate with activity against HSV, human papillomavirus (HPV), and HIV; (2)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $208,575 to the University of Arizona to develop an ionic liquid-based nanoemulsion containing a two-drug antiretroviral regimen for the oral and transdermal treatment of HIV infection. The key objectives are to: Develop, characterize, and evaluate in vitro a nanoemulsion of carnitine ionic liquids containing the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $216,759.00 to develop and evaluate a transdermal nanoemulsion-based gel formulation containing the antiretroviral drugs dolutegravir (DTG) and rilpivirine (RPV) for the long-term management of HIV infection in pediatric patients. The grant aims to: 1) develop and characterize nanoemulsion-based gel formulations containing RPV ionic liquids and...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a potentially curative gene editing therapy for latent Herpes Simplex Virus type 2 (HSV-2) infection. The $303,731 grant to Caladan Therapeutics, Inc. supports research to select an optimized meganuclease variant that can effectively target and eliminate latent HSV-2 DNA in ganglionic neurons, which is the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will provide $236,292 to Tufts University School of Medicine to characterize the structures of key herpes simplex virus (HSV) glycoprotein complexes involved in viral cell entry. The research aims to use novel methods to isolate and stabilize the GD/GH/GL and GH/GL/GB glycoprotein complexes, and then determine their...
The U.S. Defense Health Agency awarded a $1,753,267.00 Project Grant to Vaxsyna, Inc., a small disadvantaged, woman-owned business, to develop a plant-made vaccine for the prevention of Herpes Simplex Virus (HSV). This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform healthcare for the U.S. military and the public. The grant's period of performance is from August 1, 2023, to July 31, 2027, indicating a...
This $1,486,800 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research by Albert Einstein College of Medicine into antibody-dependent cell-mediated cytotoxicity (ADCC) for vaccine development against herpes simplex virus (HSV). The project aims to investigate the role of TNFRSF14 signaling in promoting ADCC responses and develop new strategies for future vaccine and...
This $2,178,000 federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a "tunable nanophage platform" for rapid vaccine design and screening against emerging infectious disease threats. The key objectives are to engineer "second generation" nanophage particles that can display the spike receptor binding domains of SARS-CoV-2 and...
This federal Cooperative Agreement award, totaling $59,956,646.00 and issued by the National Institutes of Health (NIH) under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384), supports the development of innovative machine learning-enabled vaccine design approaches targeting herpesviruses. The University of Washington is the prime awardee, collaborating with the University of Texas at Austin and Dartmouth College as sub-awardees. The key objectives are to develop...